Palisade Bio_Logos(4.22)VSM.png
Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study
May 11, 2023 09:05 ET | Palisade Bio, Inc.
Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy Company expects enrollment to be...